CanTx and Novogen expect to document an Investigational New Medication software for Cantrixil early next year and to advance this compound into the clinic by mid – 2015. Cantrixil, being developed by CanTx Inc, a joint venture company between Novogen and Yale University, has been developed to take care of cancers wholly or largely confined to the tummy specifically. It is made up of the active drug, Trx-1, included within a cyclodextrin carrier and will be injected in to the peritoneal cavity of patients. If shown to be as safe and as effective in clinical studies as it has in pet studies, Cantrixil may be the first anti-cancer medication approved as an intra-peritoneal therapy. The potential of Cantrixil provides emerged from studies at Yale, where researchers are suffering from ground-breaking screening equipment to assess new drug candidates in the treatment of ovarian cancer.Kinneret Savitsky, CEO of BioLineRx.

Boston University launches $10M, 5-year Global Wellness Center Boston University on Mon launched a five-year, $10 million global wellness initiative that aims to ‘bolster analysis and education’ and ‘create a nationwide consortium of universities specialized in improving wellness in the 3rd World,’ the Boston World reports. The new Middle for Global Health insurance and Development will draw professionals from a number of different fields, including medicine, public wellness, engineering, social function and education ‘to grapple with illnesses that cause an incredible number of deaths every year in the developing globe,’ the newspaper writes.